Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Các biện pháp thuế quan do chính quyền Tổng thống Mỹ Donald Trump đe dọa áp dụng đối với lĩnh vực dược phẩm có thể dẫn đến ...
KEY TAKEAWAYS Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss ...
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback